AL2846 capsule vs placebo for advanced thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This study tests a new oral capsule (AL2846) against a placebo in people with advanced thyroid cancer that no longer responds to radioactive iodine. The goal is to see if AL2846 can slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of thyroid cancer called differentiated thyroid cancer (like papillary or follicular) that has spread and cannot be removed by surgery.
- Your cancer must be considered 'radioactive iodine-refractory' (no longer responds to radioactive iodine treatment).
- You are between 18 and 74 years old.
- You are physically able to take care of yourself (ECOG score 0 or 1).
- Your cancer has grown after receiving no more than 2 previous lines of targeted therapy (VEGFR TKIs, such as lenvatinib or sorafenib).
- You have adequate kidney, liver, and blood cell counts as shown by standard lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral and infused drugs to slow or shrink advanced thyroid cancer that has stopped responding to initial treatment. It may offer a new option for people with limited choices.
This trial tests two oral medications, avutometinib and defactinib, for people with advanced thyroid cancer that has specific genetic changes. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests a new way to choose chemotherapy for thyroid cancer by growing a 'mini-tumor' (organoid) from your biopsy and testing different drugs on it. The goal is to find the drug that is most likely to shrink your cancer.
This trial studies anlotinib in people with advanced or metastatic medullary thyroid cancer that has been getting worse. It aims to see how well the treatment controls the cancer and how safe it is for patients who can’t have curative surgery.
This study tests if a man-made hormone (rhTSH) can make radioactive iodine therapy more effective for people with advanced thyroid cancer that has come back or spread. It aims to see if it helps find and treat cancer that doesn't respond well to standard radioactive iodine.
This trial tests whether a medicine called recombinant human thyroid stimulating hormone (rhTSH) can help prepare your body for radioactive iodine (131I) treatment, which aims to destroy any remaining or spreading thyroid cancer cells. It may be a good option if your thyroid cancer has come back or spread and you are able to have radioactive iodine therapy.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.